Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646331 | 0.84 | GAA (0.51) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL21202073 | 0.83 | GAA (0.46) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL18457715 | 0.83 | GAA (0.45) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL21202053 | 0.77 | GAA (0.43) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL12945025 | 0.77 | GAA (0.38) | GAAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL12588924 | 0.74 | GAA (0.42) | GAAOPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL18458096 | 0.71 | GAA (0.44) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL10066077 | 0.71 | GAA (0.54) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL20170710 | 0.71 | GAA (0.42) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL22058061 | 0.70 | GAA (0.41) | GAAOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363251-B2 | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof | MALLINCKRODT LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT ENTERPRISES LLC | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | GAA 1100/4885OPRM1 5/4885OPRD1 13/4885 |
| US-10363251-B2 | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof | TLR9, TLR3, TLR7 | GAA 1006/4885OPRM1 30/4885OPRD1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.